E. A. Zaki, Magdi and A. Al-Hussain, Sami and A. Al-Mutairi, Aamal and Samad, Abdul and H. Masand, Vijay and G. Ingle, Rahul and Digamber Rathod, Vivek and Maruti Gaikwad, Nikita and Rashid, Summya and N. Khatale, Pravin and V. Burakale, Pramod and D. Jawarkar, Rahul (2024) Application of in-silico drug discovery techniques to discover a novel hit for target-specific inhibition of SARS-CoV-2 Mpro’s revealed allosteric binding with MAO-B receptor: A theoretical study to find a cure for post-covid neurological disorder. PLOS ONE, 19 (1).
Text (Research Article)
journal.pone.0286848.pdf - Published Version Download (6MB) |
Abstract
Several studies have revealed that SARS-CoV-2 damages brain function and produces significant neurological disability. The SARS-CoV-2 coronavirus, which causes COVID-19, may infect the heart, kidneys, and brain. Recent research suggests that monoamine oxidase B (MAO-B) may be involved in metabolomics variations in delirium-prone individuals and severe SARS-CoV-2 infection. In light of this situation, we have employed a variety of computational to develop suitable QSAR model using PyDescriptor and genetic algorithm-multilinear regression (GA-MLR) models (R2 = 0.800–793, Q2LOO = 0.734–0.727, and so on) on the data set of 106 molecules whose anti-SARS-CoV-2 activity was empirically determined. QSAR models generated follow OECD standards and are predictive. QSAR model descriptors were also observed in x-ray-resolved structures. After developing a QSAR model, we did a QSAR-based virtual screening on an in-house database of 200 compounds and found a potential hit molecule. The new hit’s docking score (-8.208 kcal/mol) and PIC50 (7.85 M) demonstrated a significant affinity for SARS-CoV-2’s main protease. Based on post-covid neurodegenerative episodes in Alzheimer’s and Parkinson’s-like disorders and MAO-B’s role in neurodegeneration, the initially disclosed hit for the SARS-CoV-2 main protease was repurposed against the MAO-B receptor using receptor-based molecular docking, which yielded a docking score of -12.0 kcal/mol. This shows that the compound that inhibits SARS-CoV-2’s primary protease may bind allosterically to the MAO-B receptor. We then did molecular dynamic simulations and MMGBSA tests to confirm molecular docking analyses and quantify binding free energy. The drug-receptor complex was stable during the 150-ns MD simulation. The first computational effort to show in-silico inhibition of SARS-CoV-2 Mpro and allosteric interaction of novel inhibitors with MAO-B in post-covid neurodegenerative symptoms and other disorders. The current study seeks a novel compound that inhibits SAR’s COV-2 Mpro and perhaps binds MAO-B allosterically. Thus, this study will enable scientists design a new SARS-CoV-2 Mpro that inhibits the MAO-B receptor to treat post-covid neurological illness.
Item Type: | Article |
---|---|
Subjects: | Q Science > QR Microbiology Q Science > QR Microbiology > QR355 Virology R Medicine > R Medicine (General) R Medicine > RB Pathology R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica |
Depositing User: | ePrints deposit |
Date Deposited: | 26 Aug 2024 13:33 |
Last Modified: | 26 Aug 2024 13:33 |
URI: | http://eprints.tiu.edu.iq/id/eprint/1481 |
Actions (login required)
View Item |